Wall Street analysts predict that Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) will report $533.39 million in sales for the current fiscal quarter, Zacks reports. Ten analysts have issued estimates for Allscripts Healthcare Solutions’ earnings, with estimates ranging from $508.70 million to $552.10 million. Allscripts Healthcare Solutions reported sales of $415.10 million during the same quarter last year, which indicates a positive year-over-year growth rate of 28.5%. The company is expected to issue its next earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Allscripts Healthcare Solutions will report full-year sales of $533.39 million for the current year, with estimates ranging from $2.16 billion to $2.22 billion. For the next financial year, analysts expect that the firm will report sales of $2.28 billion per share, with estimates ranging from $2.13 billion to $2.34 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Allscripts Healthcare Solutions.
Allscripts Healthcare Solutions (NASDAQ:MDRX) last posted its quarterly earnings results on Thursday, February 15th. The software maker reported $0.18 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.18. Allscripts Healthcare Solutions had a positive return on equity of 7.36% and a negative net margin of 10.88%. The business had revenue of $547.00 million for the quarter, compared to the consensus estimate of $524.05 million. During the same quarter in the prior year, the company earned $0.14 EPS. The business’s revenue was up 27.5% compared to the same quarter last year.
A number of equities analysts have recently issued reports on MDRX shares. BidaskClub raised Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating in a research report on Wednesday, December 20th. Citigroup started coverage on Allscripts Healthcare Solutions in a research report on Thursday, January 4th. They set a “buy” rating on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $17.00 price target on shares of Allscripts Healthcare Solutions in a research report on Monday, January 8th. Maxim Group restated a “buy” rating and set a $20.00 price objective on shares of Allscripts Healthcare Solutions in a research note on Tuesday, January 9th. Finally, Royal Bank of Canada set a $19.00 price objective on Allscripts Healthcare Solutions and gave the stock a “buy” rating in a research note on Thursday, January 11th. One analyst has rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $16.09.
Allscripts Healthcare Solutions (MDRX) opened at $13.35 on Friday. Allscripts Healthcare Solutions has a 12-month low of $11.25 and a 12-month high of $16.13. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.97 and a current ratio of 0.97. The stock has a market capitalization of $2,463.19, a price-to-earnings ratio of 28.98, a PEG ratio of 1.76 and a beta of 1.20.
In other news, EVP Brian Farley sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $13.73, for a total value of $68,650.00. Following the completion of the transaction, the executive vice president now directly owns 240,672 shares in the company, valued at $3,304,426.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, President Richard J. Poulton sold 15,000 shares of the firm’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $13.53, for a total value of $202,950.00. Following the completion of the transaction, the president now owns 505,920 shares of the company’s stock, valued at $6,845,097.60. The disclosure for this sale can be found here. Company insiders own 0.75% of the company’s stock.
Large investors have recently made changes to their positions in the company. Zeke Capital Advisors LLC acquired a new stake in Allscripts Healthcare Solutions during the fourth quarter worth about $165,000. Avestar Capital LLC acquired a new stake in Allscripts Healthcare Solutions during the fourth quarter worth about $173,000. Sheaff Brock Investment Advisors LLC acquired a new stake in Allscripts Healthcare Solutions during the third quarter worth about $174,000. Quantitative Systematic Strategies LLC acquired a new stake in Allscripts Healthcare Solutions during the fourth quarter worth about $182,000. Finally, Crossmark Global Holdings Inc. acquired a new stake in Allscripts Healthcare Solutions during the third quarter worth about $187,000.
COPYRIGHT VIOLATION NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/zacks-analysts-expect-allscripts-healthcare-solutions-inc-mdrx-will-announce-quarterly-sales-of-533-39-million.html.
Allscripts Healthcare Solutions Company Profile
Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.
Get a free copy of the Zacks research report on Allscripts Healthcare Solutions (MDRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.